The delivery of biopharmaceutical products to specialized anatomical sites, such as the eye (ophthalmic) and the lungs (pulmonary), requires unique formulation strategies where the Biopharmaceutical Excipients [https://www.marketresearchfuture.com/reports/polymerase-chain-reaction-market-19212] play highly specific functional roles related to local tolerability, residence time, and membrane absorption.

Ophthalmic Drug Delivery Systems:

Delivering therapeutic proteins to the eye is challenging because the eye's natural defenses, such as tear flow and the corneal barrier, rapidly clear or block foreign substances. Excipients in ophthalmic formulations must therefore enhance drug absorption, prolong contact time, and ensure patient comfort.

• Viscosity Enhancers: Excipients such as high-molecular-weight polymers (e.g., carboxymethylcellulose, hyaluronic acid, or carbomers) are added to increase the viscosity of eye drops. This increase slows the rate at which the formulation is drained from the eye by tear flow, thus prolonging the contact time of the active ingredient with the cornea and allowing more time for absorption.

• Permeation Enhancers: These excipients can be included to temporarily loosen the tight junctions of the corneal epithelium, improving the passage of large biological molecules into the internal structures of the eye.

• Tonicity and $\text{pH}$ Adjusters: Ophthalmic solutions must be meticulously balanced for both tonicity and $\text{pH}$. Deviations from the eye's natural tear composition ($\text{pH} \approx 7.4$) can cause stinging, irritation, and reflex tearing, which would flush the medicine away. Excipients such as sodium chloride, potassium chloride, and specific buffering salts are used to ensure the formulation is iso-osmotic and has a $\text{pH}$ that maximizes both patient comfort and chemical stability.

Pulmonary Drug Delivery Systems (Inhalation):

For drugs administered via inhalation (e.g., for respiratory diseases or systemic delivery via the lungs), the formulation is often a dry powder or a suspension/solution within a device. Excipients here are crucial for aerosol performance and deposition.

• Carrier Excipients: In dry powder inhalers (DPIs), the active drug particles are often too small to be efficiently inhaled and deposited in the deep lungs; they tend to clump together or be exhaled. Carrier excipients (typically large, crystalline lactose particles) are used. The fine drug particles adhere to the surface of the larger lactose carrier. Upon inhalation, the force generated by the patient's breath causes the drug particles to detach from the carrier and travel deep into the respiratory tract, while the inert carrier deposits higher up in the mouth and throat. This de-aggregation function is vital for effective drug delivery.

• Stabilizers for Aerosols: For nebulized or pressurized metered-dose inhaler (pMDI) formulations, excipients stabilize the protein or peptide in the liquid aerosol phase, preventing aggregation that could be triggered by the high shear forces inherent in the aerosolization process.

  Related Reports